Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Consensus Rating of “Moderate Buy” by Brokerages
Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the nine brokerages that are covering the stock, MarketBeat reports. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average 1-year price objective among analysts that […]
More Stories
Maxwell Wealth Strategies Inc. Raises Holdings in Edwards Lifesciences Co. (NYSE:EW)
Maxwell Wealth Strategies Inc. increased its position in Edwards Lifesciences Co. (NYSE:EW – Free Report) by 27.4% in the 3rd...
CEVA (NASDAQ:CEVA) Cut to “Hold” at StockNews.com
StockNews.com downgraded shares of CEVA (NASDAQ:CEVA – Free Report) from a buy rating to a hold rating in a research...
Masco (NYSE:MAS) Stock Rating Lowered by StockNews.com
StockNews.com lowered shares of Masco (NYSE:MAS – Free Report) from a buy rating to a hold rating in a research...
Home Bancorp (NASDAQ:HBCP) Stock Rating Lowered by StockNews.com
StockNews.com cut shares of Home Bancorp (NASDAQ:HBCP – Free Report) from a buy rating to a hold rating in a...
ALLETE (NYSE:ALE) Earns Hold Rating from Analysts at StockNews.com
StockNews.com started coverage on shares of ALLETE (NYSE:ALE – Free Report) in a research report released on Friday. The firm...
Short Interest in Silvaco Group, Inc. (NASDAQ:SVCO) Increases By 29.8%
Silvaco Group, Inc. (NASDAQ:SVCO – Get Free Report) was the recipient of a significant increase in short interest during the...